Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line study of glecirasib + JAB-3312 versus tislelizumab + pemetrexed + carboplatin in KRAS G12C-mutant advanced non-squamous NSCLC
CTR20241931Phase 3Active
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Aug 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of glecirasib, sitneprotafib, tislelizumab, pemetrexed, carboplatin in Non-small cell lung cancer (NS-NSCLC), sponsored by Jacobio Pharmaceuticals. Started Aug 2024; status: active.
02
Drugs
glecirasibsitneprotafibtislelizumabpemetrexedcarboplatin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20241931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241931.